October 11, 2017
Biophytis completes a €10.4 M capital increase to finance mid-stage clinical trials for two novel anti-aging drug-candidates. Read the Press Release
Biophytis completes a €10.4 M capital increase to finance mid-stage clinical trials for two novel anti-aging drug-candidates. Read the Press Release
Interview of Stanislas Veillet, CEO of Biophytis for the European Large & Midcap event 2017 with Didier Testot, journalist on the Web tv www.labourseetlavie.com
Biophytis filed IND application for approval by FDA of SARA-INT Phase 2b study of Sarconeos in Sarcopenia. Read the Press Release
Biophytis to participate in upcoming industry and investors conferences. Read the Press Release
Biophytis presents the mechanism of action of Macuneos for the treatment of AMD, at the Euretina Congress. Read the Press Release
Biophytis clinical stage drug-candidate Sarconeos demonstrates efficacy in preclinical models of Duchenne muscular dystrophy . Read the Press Release
The report of the Key Opinion Leader Breakfast of july 28, in NYC with Roger Fielding, PhD (Tufts University) made available
Biophytis announces the appointment of Dr Manfred Horst as Business Development Office. Read the Press Release
2016 Reference Document made available. Read the Press Release
BIOPHYTIS selects Appletree CI Group to conduct MACA-OBS, and releases the MACA clinical program schedule of Macuneos in dry AMD. Read the Press Release